On Wednesday, The Medicines Company (NASDAQ:MDCO)’s shares inclined 3.66% to $37.96.
The Medicines Company declared that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion recommending marketing authorization for IONSYS® (40 micrograms per dose transdermal system), with active ingredient fentanyl, for the short-term administration of acute moderate-to-severe, post-operative pain in adult patients. IONSYS will be the only needle-free, patient-controlled, pre-programmed fentanyl delivery system for use in patients requiring opioid analgesia in EU hospital settings.
Effective administration of post-operative pain is a growing challenge for healthcare providers worldwide. Globally, hospitals perform 234 million major surgeries per year and about 75% of patients experience pain post-operatively. Many of these patients continue to suffer from poorly managed pain days or weeks after their procedures. For example, a comprehensive assessment of 1,490 post-surgical patients in the Netherlands demonstrated that 15% stated moderate-to-severe pain four days after their surgeries. This is comprising with data from the United States that indicated 86% of inpatient surgeries result in pain up to two weeks following the procedure.
The Medicines Company provides medicines for patients in acute and intensive care hospitals worldwide. The company markets Angiomax, an intravenous direct thrombin inhibitor used as an anticoagulant in combination with aspirin in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty, and for use in patients undergoing percutaneous coronary intervention; Cleviprex, an intravenous small molecule calcium channel blocker for blood pressure reduction; Minocin IV, an antibiotic for the treatment of infections due to gram-negative bacteria; Orbactiv for the treatment of acute bacterial skin and skin structure infections; PreveLeak, a mechanical vascular and surgical sealant; ready-to-use formulation of Argatroban for the treatment of thrombosis; and Recothrom, a human recombinant thrombin used as an aid to hemostasis, in addition to acute care generic products for acute cardiovascular, surgery and perioperative care, and serious infectious diseases.
Ocwen Financial Corp (NYSE:OCN)’s shares gained 0.30% to $6.71.
Ocwen Financial Corporation (OCN) and the NAACP New York State Conference hosted a “Assist & Hope for Homeowners” event in Long Island, NY on Saturday, September 26, 2015 to offer struggling New York homeowners the opportunity to receive in-person, individualized advice and mortgage solutions to assist them remain in their homes.
Event attendees received one-on-one support from Ocwen Home Retention Agents, who worked with more than 220 borrowers to make their mortgage payments more manageable and to assist avoid foreclosure. Since 2008, Ocwen has accomplished more than 520,000 loan modifications, many of which comprised of a principal reduction for borrowers whose mortgage exceeded the current value of the home.
Homeowners also met with the U.S. Department of Housing and Urban Development (HUD)-approved financial counselors for additional financial and mortgage-related assistance.
Ocwen Financial Corporation, a financial services holding company, engages in servicing and origination of mortgage loans in the United States. Its Servicing segment provides residential and commercial mortgage loan servicing, special servicing, and asset administration services to owners of mortgage loans and foreclosed real estate. This segments residential servicing portfolio comprises conventional, government insured, and non-agency loans.
At the end of Wednesday’s trade, St. Jude Medical, Inc. (NYSE:STJ)‘s shares surged 0.24% to $63.09.
St. Jude Medical, Inc. (STJ), a global medical device company, declared that it will report financial results for its third quarter of its fiscal year 2015 on Wednesday, October 21, 2015. A news release will be issued at about 6:15 a.m. CT and the company will hold its quarterly conference call to talk about the financial results at 7 a.m. CT (8 a.m. ET).
St. Jude Medical, Inc., together with its auxiliaries, develops, manufactures and distributes cardiovascular medical devices for cardiac rhythm administration, cardiovascular, and atrial fibrillation therapy areas worldwide. It operates in two divisions, Implantable Electronic Systems, and Cardiovascular and Ablation Technologies.
Hershey Co (NYSE:HSY), ended its Wednesday’s trading session with -0.55% loss, and closed at $91.88.
The Hershey Company (HSY) declared a new Clinton Global Initiative (CGI) Commitment to Action to train 7,500 farmers in Ghana on improved agronomic practices, empowering them to supply local commercial markets with safe and high-quality peanuts to produce Vivi, a vitamin and mineral-fortified nutritional supplement distributed to school children in Ghana. Hershey commits to 100% local sourcing of peanuts for its production of Vivi by 2018.
Providing children with the basic nutrition they need to learn, grow and be successful in school remains a challenge across West Africa. Hershey produces and distributes these much-needed nutritional supplements at no cost to the children through a partnership with the Ghana School Feeding Program and nonprofit Project Peanut Butter.
The Hershey Company manufactures, imports, markets, distributes, and sells confectionery products. The company operates through two segments, North America; and International and Other. It offers chocolate and sugar confectionery products; pantry items, such as baking ingredients, toppings, sundae syrups, and beverages; snack items, counting spreads; and gum and mint refreshment products comprising chewing gums and bubble gums.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
